{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T22:20:53Z","timestamp":1795126853270,"version":"4.10.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"8100","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2026,2,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The prevalence of Alzheimer\u2019s disease neuropathological changes (ADNCs), the leading cause of cognitive impairment, remains uncertain. Recent blood-based biomarkers enable scalable assessment of ADNCs\n                    <jats:sup>1<\/jats:sup>\n                    . Here we measured phosphorylated tau at threonine 217 in 11,486 plasma samples from a Norwegian population-based cohort of individuals over 57 years of age as a surrogate marker for ADNCs. The estimated prevalence of ADNCs increased with age, from less than 8% in people 58\u201369.9 years of age to 65.2% in those over 90 years of age. Among participants aged 70 years or older, 10% had preclinical Alzheimer\u2019s disease, 10.4% had prodromal Alzheimer\u2019s disease and 9.8% had Alzheimer\u2019s disease dementia. Furthermore, among those 70 years of age\u00a0or older, ADNCs were present in 60% of people with dementia, in 32.6% of those with mild cognitive impairment and in 23.5% of the cognitively unimpaired group. Our findings suggest a higher prevalence of Alzheimer\u2019s disease dementia in older individuals and a lower prevalence of preclinical Alzheimer\u2019s disease in younger groups than previously estimated\n                    <jats:sup>2<\/jats:sup>\n                    .\n                  <\/jats:p>","DOI":"10.1038\/s41586-025-09841-y","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T16:02:32Z","timestamp":1765987352000},"page":"182-186","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Prevalence of Alzheimer\u2019s disease pathology in the community"],"prefix":"10.1038","volume":"650","author":[{"given":"Dag","family":"Aarsland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0854-470X","authenticated-orcid":false,"given":"Anita Lenora","family":"Sunde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3490-9899","authenticated-orcid":false,"given":"Diego A.","family":"Tovar-Rios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Leuzy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9984-9797","authenticated-orcid":false,"given":"Tormod","family":"Fladby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3930-4354","authenticated-orcid":false,"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1890-4193","authenticated-orcid":false,"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9092-2118","authenticated-orcid":false,"given":"K\u00fcbra","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"De Santis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yara","family":"Yakoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burak","family":"Arslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3080-6870","authenticated-orcid":false,"given":"Hanna","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Pola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lana","family":"Gr\u00f6tschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5339-933X","authenticated-orcid":false,"given":"Guglielmo","family":"Di Molfetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3067-0016","authenticated-orcid":false,"given":"H\u00e5vard K.","family":"Skjellegrind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6511-8219","authenticated-orcid":false,"given":"Geir","family":"Selbaek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Ashton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"9841_CR1","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","volume":"81","author":"NJ Ashton","year":"2024","unstructured":"Ashton, N. J. et al. Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology. JAMA Neurol. 81, 255\u2013263 (2024).","journal-title":"JAMA Neurol."},{"key":"9841_CR2","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/alz.12694","volume":"19","author":"A Gustavsson","year":"2023","unstructured":"Gustavsson, A. et al. Global estimates on the number of persons across the Alzheimer\u2019s disease continuum. Alzheimers Dement. 19, 658\u2013670 (2023).","journal-title":"Alzheimers Dement."},{"key":"9841_CR3","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41591-024-03340-9","volume":"31","author":"M Fang","year":"2025","unstructured":"Fang, M. et al. Lifetime risk and projected burden of dementia. Nat. Med. 31, 772\u2013776 (2025).","journal-title":"Nat. Med."},{"key":"9841_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck, C. H. et al. Lecanemab in early Alzheimer\u2019s disease. N. Engl. J. Med. 388, 9\u201321 (2023).","journal-title":"N. Engl. J. Med."},{"key":"9841_CR5","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims, J. R. et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330, 512\u2013527 (2023).","journal-title":"JAMA"},{"key":"9841_CR6","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/s41591-022-01822-2","volume":"28","author":"MM Mielke","year":"2022","unstructured":"Mielke, M. M. et al. Performance of plasma phosphorylated tau 181 and 217 in the community. Nat. Med. 28, 1398\u20131405 (2022).","journal-title":"Nat. Med."},{"key":"9841_CR7","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.1093\/ije\/dyac095","volume":"52","author":"BO Asvold","year":"2023","unstructured":"Asvold, B. O. et al. Cohort profile update: the HUNT study, Norway. Int. J. Epidemiol. 52, e80\u2013e91 (2023).","journal-title":"Int. J. Epidemiol."},{"key":"9841_CR8","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyae073","volume":"53","author":"M Naess","year":"2024","unstructured":"Naess, M. et al. Data resource profile: the HUNT Biobank. Int. J. Epidemiol. 53, dyae073 (2024).","journal-title":"Int. J. Epidemiol."},{"key":"9841_CR9","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14283\/jpad.2023.30","volume":"10","author":"J Cummings","year":"2023","unstructured":"Cummings, J. et al. Lecanemab: appropriate use recommendations. J. Prev. Alzheimers Dis. 10, 362\u2013377 (2023).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"9841_CR10","doi-asserted-by":"crossref","unstructured":"Rabinovici, G. et al. Donanemab: appropriate use recommendation. J. Prev. Alzheimers Dis. 12, 100150 (2025).","DOI":"10.1016\/j.tjpad.2025.100150"},{"key":"9841_CR11","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.3233\/JAD-201275","volume":"79","author":"L Gj\u00d8ra","year":"2021","unstructured":"Gj\u00d8ra, L. et al. Current and future prevalence estimates of mild cognitive impairment, dementia, and its subtypes in a population-based sample of people 70 years and older in Norway: the HUNT study. J. Alzheimers Dis. 79, 1213\u20131226 (2021).","journal-title":"J. Alzheimers Dis."},{"key":"9841_CR12","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41582-024-00977-5","volume":"20","author":"SE Schindler","year":"2024","unstructured":"Schindler, S. E. et al. Acceptable performance of blood biomarker tests of amyloid pathology \u2014 recommendations from the Global CEO Initiative on Alzheimer\u2019s Disease. Nat. Rev. Neurol. 20, 426\u2013439 (2024).","journal-title":"Nat. Rev. Neurol."},{"key":"9841_CR13","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist, S. et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 324, 772\u2013781 (2020).","journal-title":"JAMA"},{"key":"9841_CR14","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13195-025-01692-z","volume":"17","author":"B Arslan","year":"2025","unstructured":"Arslan, B. et al. The impact of kidney function on Alzheimer\u2019s disease blood biomarkers: implications for predicting amyloid-\u03b2 positivity. Alzheimers Res. Ther. 17, 48 (2025).","journal-title":"Alzheimers Res. Ther."},{"key":"9841_CR15","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1136\/jnnp-2024-333467","volume":"95","author":"S Lehmann","year":"2024","unstructured":"Lehmann, S. et al. Clinical value of plasma ALZpath pTau217 immunoassay for assessing mild cognitive impairment. J. Neurol. Neurosurg. Psychiatry 95, 1046\u20131053 (2024).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"9841_CR16","doi-asserted-by":"publisher","first-page":"e1004568","DOI":"10.1371\/journal.pmed.1004568","volume":"22","author":"R Tonegawa-Kuji","year":"2025","unstructured":"Tonegawa-Kuji, R. et al. Efficacy and safety of passive immunotherapies targeting amyloid \u03b2 in Alzheimer\u2019s disease: a systematic review and meta-analysis. PLoS Med. 22, e1004568 (2025).","journal-title":"PLoS Med."},{"key":"9841_CR17","doi-asserted-by":"publisher","first-page":"9649","DOI":"10.1073\/pnas.90.20.9649","volume":"90","author":"DE Schmechel","year":"1993","unstructured":"Schmechel, D. E. et al. Increased amyloid \u03b2-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc. Natl Acad. Sci. USA 90, 9649\u20139653 (1993).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"9841_CR18","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1006\/exnr.1998.6860","volume":"153","author":"E Ghebremedhin","year":"1998","unstructured":"Ghebremedhin, E., Schultz, C., Braak, E. & Braak, H. High frequency of apolipoprotein E \u03b54 allele in young individuals with very mild Alzheimer\u2019s disease-related neurofibrillary changes. Exp. Neurol. 153, 152\u2013155 (1998).","journal-title":"Exp. Neurol."},{"key":"9841_CR19","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.3233\/JAD-180141","volume":"64","author":"CR Beam","year":"2018","unstructured":"Beam, C. R. et al. Differences between women and men in incidence rates of dementia and Alzheimer\u2019s disease. J. Alzheimers Dis. 64, 1077\u20131083 (2018).","journal-title":"J. Alzheimers Dis."},{"key":"9841_CR20","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/j.jalz.2018.07.219","volume":"16","author":"Y Stern","year":"2020","unstructured":"Stern, Y. et al. Whitepaper: defining and investigating cognitive reserve, brain reserve, and brain maintenance. Alzheimers Dement. 16, 1305\u20131311 (2020).","journal-title":"Alzheimers Dement."},{"key":"9841_CR21","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(24)01296-0","volume":"404","author":"G Livingston","year":"2024","unstructured":"Livingston, G. et al. Dementia prevention, intervention, and care: 2024 report of the Lancet Standing Commission. Lancet 404, 572\u2013628 (2024).","journal-title":"Lancet"},{"key":"9841_CR22","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1001\/archneur.63.11.1551","volume":"63","author":"A Akomolafe","year":"2006","unstructured":"Akomolafe, A. et al. Diabetes mellitus and risk of developing Alzheimer disease: results from the Framingham Study. Arch. Neurol. 63, 1551\u20131555 (2006).","journal-title":"Arch. Neurol."},{"key":"9841_CR23","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1001\/archneur.62.10.1556","volume":"62","author":"M Kivipelto","year":"2005","unstructured":"Kivipelto, M. et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch. Neurol. 62, 1556\u20131560 (2005).","journal-title":"Arch. Neurol."},{"key":"9841_CR24","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr","year":"2024","unstructured":"Jack, C. R. Jr et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement. 20, 5143\u20135169 (2024).","journal-title":"Alzheimers Dement."},{"key":"9841_CR25","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/S1474-4422(22)00168-5","volume":"21","author":"R Ossenkoppele","year":"2022","unstructured":"Ossenkoppele, R., van der Kant, R. & Hansson, O. Tau biomarkers in Alzheimer\u2019s disease: towards implementation in clinical practice and trials. Lancet Neurol. 21, 726\u2013734 (2022).","journal-title":"Lancet Neurol."},{"key":"9841_CR26","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1001\/jamaneurol.2024.5017","volume":"82","author":"L VandeVrede","year":"2025","unstructured":"VandeVrede, L. et al. Detection of Alzheimer neuropathology in Alzheimer and non-Alzheimer clinical syndromes with blood-based biomarkers. JAMA Neurol. 82, 344\u2013354 (2025).","journal-title":"JAMA Neurol."},{"key":"9841_CR27","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","volume":"20","author":"EH Thijssen","year":"2021","unstructured":"Thijssen, E. H. et al. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer\u2019s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol 20, 739\u2013752 (2021).","journal-title":"Lancet Neurol"},{"key":"9841_CR28","doi-asserted-by":"publisher","first-page":"e594","DOI":"10.1212\/WNL.0000000000200678","volume":"99","author":"BM Asken","year":"2022","unstructured":"Asken, B. M. et al. Plasma P-tau181 and P-tau217 in patients with traumatic encephalopathy syndrome with and without evidence of Alzheimer disease pathology. Neurology 99, e594\u2013e604 (2022).","journal-title":"Neurology"},{"key":"9841_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-023-02570-4","volume":"146","author":"L Yu","year":"2023","unstructured":"Yu, L. et al. Plasma p-tau181 and p-tau217 in discriminating PART, AD and other key neuropathologies in older adults. Acta Neuropathol. 146, 1\u201311 (2023).","journal-title":"Acta Neuropathol."},{"key":"9841_CR30","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/s43587-024-00731-y","volume":"4","author":"J Therriault","year":"2024","unstructured":"Therriault, J. et al. Diagnosis of Alzheimer\u2019s disease using plasma biomarkers adjusted to clinical probability. Nat Aging 4, 1529\u20131537 (2024).","journal-title":"Nat Aging"},{"key":"9841_CR31","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1038\/s41591-025-03622-w","volume":"31","author":"S Palmqvist","year":"2025","unstructured":"Palmqvist, S. et al. Plasma phospho-tau217 for Alzheimer\u2019s disease diagnosis in primary and secondary care using a fully automated platform. Nat. Med. 31, 2036\u20132043 (2025).","journal-title":"Nat. Med."},{"key":"9841_CR32","doi-asserted-by":"publisher","first-page":"e70038","DOI":"10.1002\/alz.70038","volume":"21","author":"J Wang","year":"2025","unstructured":"Wang, J. et al. Diagnostic accuracy of plasma p-tau217\/A\u03b242 for Alzheimer\u2019s disease in clinical and community cohorts. Alzheimers Dement. 21, e70038 (2025).","journal-title":"Alzheimers Dement."},{"key":"9841_CR33","doi-asserted-by":"publisher","first-page":"105805","DOI":"10.1016\/j.ebiom.2025.105805","volume":"117","author":"S Lehmann","year":"2025","unstructured":"Lehmann, S. et al. Comparative performance of plasma pTau181\/A\u03b242, pTau217\/A\u03b242 ratios, and individual measurements in detecting brain amyloidosis. eBioMedicine 117, 105805 (2025).","journal-title":"eBioMedicine"},{"key":"9841_CR34","volume":"15","author":"AL Sunde","year":"2023","unstructured":"Sunde, A. L. et al. Preanalytical stability of plasma biomarkers for Alzheimer\u2019s disease pathology. Alzheimers Dement. 15, e12439 (2023).","journal-title":"Alzheimers Dement."},{"key":"9841_CR35","doi-asserted-by":"publisher","first-page":"e70173","DOI":"10.1002\/alz.70173","volume":"21","author":"DJ Figdore","year":"2025","unstructured":"Figdore, D. J. et al. Differences in Alzheimer\u2019s disease blood biomarker stability: implications for the use of tau\/amyloid ratios. Alzheimers Dement. 21, e70173 (2025).","journal-title":"Alzheimers Dement."},{"key":"9841_CR36","first-page":"e12270","volume":"8","author":"WS Brum","year":"2022","unstructured":"Brum, W. S. et al. A three-range approach enhances the prognostic utility of CSF biomarkers in Alzheimer\u2019s disease. Alzheimers Dement. 8, e12270 (2022).","journal-title":"Alzheimers Dement."},{"key":"9841_CR37","doi-asserted-by":"publisher","first-page":"e70113","DOI":"10.1002\/alz.70113","volume":"21","author":"J Hazan","year":"2025","unstructured":"Hazan, J., Liu, K. Y., Isaacs, J. D. & Howard, R. Cut-points and gray zones: the challenges of integrating Alzheimer\u2019s disease plasma biomarkers into clinical practice. Alzheimers Dement. 21, e70113 (2025).","journal-title":"Alzheimers Dement."},{"key":"9841_CR38","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s00401-014-1349-0","volume":"128","author":"JF Crary","year":"2014","unstructured":"Crary, J. F. et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 128, 755\u2013766 (2014).","journal-title":"Acta Neuropathol."},{"key":"9841_CR39","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1177\/08982643221131926","volume":"35","author":"V Skirbekk","year":"2023","unstructured":"Skirbekk, V. et al. Marital histories and associations with later-life dementia and mild cognitive impairment risk in the HUNT4 70+ study in Norway. J. Aging Health 35, 543\u2013555 (2023).","journal-title":"J. Aging Health"},{"key":"9841_CR40","unstructured":"Valliant, R. & Dever, J. A. Survey Weights: a Step-by-Step Guide to Calculation (Stata Press, 2017)."},{"key":"9841_CR41","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","volume":"385","author":"LA Inker","year":"2021","unstructured":"Inker, L. A. et al. New creatinine- and cystatin C-based equations to estimate GFR without race. N. Engl. J. Med. 385, 1737\u20131749 (2021).","journal-title":"N. Engl. J. Med."}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-09841-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-09841-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-09841-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T12:28:09Z","timestamp":1770208089000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-09841-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":41,"journal-issue":{"issue":"8100","published-print":{"date-parts":[[2026,2,5]]}},"alternative-id":["9841"],"URL":"https:\/\/doi.org\/10.1038\/s41586-025-09841-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6153769\/v1","asserted-by":"object"}]},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"assertion":[{"value":"4 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.A. has received research support and\/or honoraria from AstraZeneca, H. Lundbeck, Novartis Pharmaceuticals, Evonik, Roche Diagnostics, GE Health, Bioarctic and Sanofi; and served as a paid consultant for H. Lundbeck, Eisai, Heptares, Mentis Cura, Eli Lilly, Cognetivity, Enterin, Acadia, EIP Pharma, Biogen and Takeda. A.L. has acted as a consultant for Enigma Biomedical Group. H.Z. has served on scientific advisory boards and\/or as a consultant for AbbVie, Acumen, Alector, Alzinova, ALZpath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Enigma, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Quanterix, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics and Wave; has given lectures sponsored by Alzecure, BioArctic, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, Roche and WebMD; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside the submitted work). K.B. has served as a consultant and on advisory boards for AbbVie, AC Immune, ALZPath, AriBio, Beckman-Coulter, BioArctic, Biogen, Eisai, Lilly, Moleac, Neurimmune, Novartis, Ono Pharma, Prothena, Quanterix, Roche Diagnostics, Sanofi and Siemens Healthineers; has served on data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. G.S. has participated in advisory board meetings for Roche, Eli-Lilly and Eisai regarding disease-modifying drugs for AD; and has received honoraria for delivering lectures at symposia sponsored by Eisai and Eli-Lilly. N.J.A. has given lectures, produced educational materials and participated in educational programs for Eli-Lily, BioArtic and Quanterix. A.L.S., D.A.T.R., T.F., K.T., G.D.S., L.G., Y.Y., B.A., H.H., I.P., G.D.M. and H.K.S. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}